Last reviewed · How we verify
NCT06114563
Effects of Yogurt With Spirulina on Cardiometabolic Risk Markers
NA trial testing Spirulina yogurt in Overweight and Obesity in 64 participants. Completed in 15 September 2023.
31 July 2023
Quick facts
| Lead sponsor | Agricultural University of Athens |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 1 February 2023 |
| Primary completion | 31 July 2023 |
| Estimated completion | 15 September 2023 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Spirulina yogurt
- Conventional yogurt
Conditions studied
- Overweight and Obesity — all drugs for Overweight and Obesity →
- PreDiabetes — all drugs for PreDiabetes →
- Hypertension — all drugs for Hypertension →
- Dyslipidemias — all drugs for Dyslipidemias →
Sponsor
Agricultural University of Athens
Who can join
Adults 18 to 70, any sex, with Overweight and Obesity or PreDiabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The effects of yogurt with spirulina consumption compared to conventional yogurt (without spirulina) on several cardiometabolic and anthropometric parameters in individuals at risk of cardiovascular disease
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06114563
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overweight and Obesity
Currently open trials in the same condition.
- NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
- NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other Agricultural University of Athens trials
Trials by the same sponsor.
- NCT06163937 — Acute Effects of Fruit Juices Consumption on Postprandial Glycemic Responses and Satiety · NA · completed
- NCT05866744 — Effects of Time-restricted Hypocaloric Diet in Patients with NAFLD · NA · completed
- NCT06114576 — Effects of Biofunctional Orange Juice on Cardiometabolic Risk Markers · NA · completed
- NCT05928741 — Short-term Effects of Juice Consumption With Biofunctional Compounds and Probiotics on Subjective Appetite · NA · completed
- NCT05702359 — Acute Effects of Juice Consumption With Biofunctional Compounds and Probiotics on Glucose Metabolism · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06114563 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Agricultural University of Athens
- Last refreshed: 11 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06114563.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing